In Brief: Aviron intranasal influenza vaccine
Executive Summary
Aviron intranasal influenza vaccine: Phase III trial will enroll over 900 children aged 15-71 months by year-end, Mountain View, Calif.-based Aviron announces Aug. 26. Aviron will conduct the randomized, double-blind, placebo-controlled trial in collaboration with the National Institute of Allergy & Infectious Disease; Aviron entered a Collaborative Research & Development Agreement with NIAID in 1995. The pivotal trial will test the "reduction of disease associated with influenza virus infection," examining illness including fever, respiratory tract symptoms, muscle aches, chills, decreased activity and irritability. Phase III trials of the intranasal vaccine in the elderly and adults are planned for 1997. Aviron will seek funding through a small private placement this autumn or through a public offering if the stock market improves. The company postponed an initial public offering in July...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth